Drug intelligence / Profile preview

docetaxel + nimotuzumab

Development stage: Unknown
Lead developer: Biotech Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of docetaxel, a taxane chemotherapy agent that disrupts cell division by stabilizing microtubules, and nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). This combination has been studied in various cancer types including head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), and non-small-cell lung cancer (NSCLC).

Targets

TUBB (Tubulin (alpha and beta subunits))EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on docetaxel + nimotuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + nimotuzumab.

Explore the full profile